Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Dyslipidemia remains a primary driver of atherosclerosis, with suboptimal LDL-cholesterol control in many ischemic heart disease patients despite therapy.
• The EUROASPIRE surveys highlight persistent challenges in achieving lipid goals for patients with ischemic heart disease.
• Current lipid-lowering therapies, including statins, show limitations in reaching target LDL-cholesterol levels for a significant patient cohort.

Purpose of the Study:

• To review the efficacy and safety of rosuvastatin across the cardiovascular disease continuum.
• To evaluate rosuvastatin's role in managing dyslipidemia and preventing atherosclerotic events.
• To emphasize the benefits of early intervention with rosuvastatin in cardiovascular disease management.

Main Methods:

• Review of clinical trial data, including the GALAXY program, investigating rosuvastatin's effects.
• Analysis of rosuvastatin's impact on lipid profiles (LDL-C, HDL-C, triglycerides, total cholesterol, apolipoproteins).
• Assessment of rosuvastatin's efficacy and safety in various stages of the cardiovascular continuum.

Main Results:

• Rosuvastatin demonstrates potent LDL-cholesterol reduction, surpassing other statins.
• It offers comprehensive lipid profile improvements, including increased HDL-cholesterol and decreased triglycerides.
• The GALAXY program data underscore the advantages of initiating rosuvastatin treatment early in the cardiovascular continuum.

Conclusions:

• Rosuvastatin is an effective and safe option for managing dyslipidemia and improving lipid profiles.
• Early treatment with rosuvastatin is vital for maximizing benefits across the cardiovascular disease spectrum.
• Addressing LDL-cholesterol goals remains critical, and potent statins like rosuvastatin play a key role in achieving them.